查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438216

2030 年布氏桿菌症疫苗市场预测：按疫苗类型、疾病、通路、应用、最终用户和地区进行的全球分析

Brucellosis Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type, Disease, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球布氏桿菌症疫苗市场规模为 2.396 亿美元，预测期内复合年增长率为 6.70%，到 2030 年将达到 3.774 亿美元。

布氏桿菌症疫苗是针对布氏桿菌属的预防措施，布鲁氏菌病是一种影响动物和人类的通用感染疾病的病原体。此疫苗主要用于牛、山羊和绵羊等牲畜。疫苗有助于控制布氏桿菌属感染的传播，并降低接触受污染的动物食品或直接接触受感染的动物而传播给人类的风险。

美国农业部 (USDA) 报告称，美国约有 9,190 万头牛和牛。同样，根据美国农业部的一份报告，印度的牛存栏量预计将增加，到 2022 年将达到 3.067 亿头。

布鲁氏菌病流行

布鲁氏菌病在全世界构成重大健康和经济威胁，特别是在人类和动物密切接触的地区，增加了对有效疫苗的需求。各国政府、牲畜所有者和卫生保健机构越来越认识到透过疫苗接种来控制布氏桿菌症传播的重要性。这种认知的提高，加上对永续农业实践的日益增长的需求，正在推动相关人员积极寻求和投资创新的疫苗解决方案，以减少这种感染疾病的影响，从而推动布氏桿菌症疫苗市场的扩张。

抗生素治疗选择

抗生素治疗选择作为布氏桿菌症疫苗市场的限制因素发挥关键作用。强力霉素和利福平等抗生素对于控制和治疗人类感染疾病至关重要。对抗菌治疗的依赖可能会阻碍布氏桿菌症疫苗市场的成长，因为有效的药物可以提供快速作用并减少预防性疫苗接种的需求。此外，开发普遍有效的布氏桿菌症疫苗所面临的挑战进一步强调了抗菌疗法对于解决疾病当前负担的重要性。

不断发展的畜牧业

随着全球对肉类和乳製品的需求不断增加，畜牧农民正在努力确保牛的健康和生产力。布鲁氏菌病导致牛和羊的繁殖问题，导致畜牧业的经济损失。有效的布氏桿菌症疫苗的开发和普及将提供预防性解决方案，减少疾病的流行，并促进牲畜的整体福祉。畜牧农民越来越重视疾病管理，以提高牲畜经营的永续性和盈利，为疫苗製造商创造了一个利润丰厚的市场。

认识和教育有限

布氏桿菌症疫苗市场的认识和教育有限的威胁源于相关人员（包括医疗保健相关人员和公众）的知识和理解不足。这种认识的缺乏可能会阻碍布氏桿菌症疫苗的采用并导致疫苗接种率低。对布氏桿菌症的严重性和疫苗接种益处的教育不足可能会导致低估该疾病的影响并阻碍控制其传播的努力。应对这项威胁需要进行有针对性的教育宣传活动，以提高医疗保健提供者、政策制定者和一般民众的意识。

COVID-19 的影响：

由于资源和重点已转移到应对全球健康危机上，布氏桿菌症疫苗的开发、生产和分销已陷入停滞。研究和投资重点正在发生变化，影响布氏桿菌症疫苗的整体进展和可用性。此外，供应链中断和后勤挑战进一步阻碍了疫苗的取得。随着对抗 COVID-19 的斗争继续进行，布氏桿菌症疫苗市场面临延误和不确定性，可能会影响人类和动物群体中这种细菌感染的控制。

预计病毒性疾病领域在预测期内将是最大的

由于人们对这种细菌感染疾病的认识和努力的提高，病毒性疾病领域正在经历显着的增长。此外，针对布氏桿菌属的创新研究和发展导致了投资和进展的激增。此外，这种增长是由製药公司、研究机构和政府为解决布氏桿菌症引起的重大公共卫生问题而采取的合作方法所推动的。

动物照护中心产业预计在预测期内复合年增长率最高

由于人们认识的提高和控制动物布氏桿菌症传播的积极措施，动物护理中心行业正在经历显着增长。随着对动物健康和福利的日益重视，兽医院和护理中心正在积极将布氏桿菌症疫苗接种计划纳入其服务中。这一激增也是由旨在减少布氏桿菌症对经济和公共卫生影响的监管努力所推动的。此外，随着牲畜和伴同性动物饲主寻求预防解决方案，动物照护中心对布氏桿菌症疫苗的需求正在增加。

占比最高的地区

北美在全球市场中占据主导地位，预计在预测期内将保持其地位。成长的潜在因素包括布氏桿菌症预防意识的提高、对牲畜健康管理的需求增加以及政府促进动物健康的措施。该地区先进的兽医基础设施和研究能力也促进了布氏桿菌症疫苗的开发和采用。畜牧业是该地区疫苗接种需求的主要动力。生物学研究鼓励针对动物福利的疾病特异性疫苗的开发。

复合年增长率最高的地区：

预计亚太地区市场在预测期内将以显着的成长率扩大。这一增长归因于该地区（尤其是中国）肉类消费和贸易的持续增长。中国对肉类的需求不断增长，使其成为养殖动物动物保健品的最大市场之一。对乳製品和肉类产品的需求不断增加，加上畜牧业生产的激增，正在推动对有效疫苗的需求。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第四章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间存在敌对关係

第五章全球布氏桿菌症疫苗市场：依疫苗类型

  • DNA疫苗
  • 次单位疫苗
    • 结合疫苗
    • 重组疫苗
    • 类毒素疫苗
  • 无效
  • 活腐烂
  • mRNA疫苗
  • 载体疫苗
  • 病毒载体疫苗
  • 其他类型的疫苗

第六章全球布氏桿菌症疫苗市场：依疾病分类

  • 病毒性疾病
    • COVID-19
    • 肝炎
    • 带状疱疹
    • 人类乳突病毒
    • 麻疹、腮腺炎、德国麻疹
    • 流感
    • 轮状病毒
    • 其他病毒性疾病
  • 细菌疫苗
    • 白喉 百日咳 破伤风
    • 肺炎球菌疾病
    • 脑膜炎球菌疾病
    • 其他细菌疫苗
  • 过敏疫苗
  • 癌症疫苗
  • 其他疾病

第七章全球布氏桿菌症疫苗市场：依通路分类

  • 医院和零售药房
  • 政府供应商
  • 其他分销管道

第八章全球布氏桿菌症疫苗市场：依应用分类

  • 牛
  • 山羊
  • 马
  • 羊
  • 猪
  • 其他用途

第九章全球布氏桿菌症疫苗市场：依最终用户分类

  • 兽医医院和诊所
  • 动物保护中心
  • 其他最终用户

第十章全球布氏桿菌症疫苗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Biogenesis-Bago
  • Biovet
  • Boehringer Ingelheim
  • Calier
  • Ceva Sante Animale
  • Colorado Serum
  • CZ Veterinaria
  • Hester Biosciences
  • Indian Immunologicals
  • Onderstepoort Biological
  • Qilu
  • SYVA Laboratorios
  • Technovax
  • Zoetis
Product Code: SMRC25185

According to Stratistics MRC, the Global Brucellosis Vaccine Market is accounted for $239.6 million in 2023 and is expected to reach $377.4 million by 2030 growing at a CAGR of 6.70% during the forecast period. The Brucellosis vaccine is a preventive measure against Brucella bacteria, which cause brucellosis-a zoonotic disease affecting animals and humans. The vaccine is primarily administered to livestock such as cattle, goats, and sheep, as these animals are common reservoirs for the bacteria. The vaccine helps control the spread of brucella infections, reducing the risk of transmission to humans through contact with contaminated animal products or direct contact with infected animals.

According to the report of the United States Department of Agriculture (USDA), there were about 91.9 million cattle and calves in the United States. Similarly, report of the USDA, the population of cattle in India is expected to increase and reach 306.7 million in 2022.

Market Dynamics:

Driver:

Prevalence of brucellosis

With Brucellosis posing substantial health and economic threats globally, particularly in regions with close human-animal interaction, the demand for effective vaccines has risen. Governments, livestock owners, and healthcare authorities are increasingly recognizing the importance of prevention through vaccination to control the spread of Brucellosis. This heightened awareness, coupled with a growing need for sustainable agricultural practices, fuels the expansion of the brucellosis vaccine market as stakeholders actively seek and invest in innovative vaccine solutions to mitigate the impact of this infectious disease.

Restraint:

Antimicrobial treatment options

Antimicrobial treatment options play a crucial role in the restraint of the Brucellosis vaccine market. Antibiotics such as doxycycline and rifampin are essential for managing and treating the infection in humans. This reliance on antimicrobial therapies may hinder the growth of the Brucellosis vaccine market, as effective drugs can provide immediate relief and may reduce the perceived need for preventive vaccination. Additionally, challenges in developing a universally effective brucellosis vaccine further emphasize the significance of antimicrobial treatments in addressing the current burden of the disease.

Opportunity:

Growing livestock industry

As the demand for meat and dairy products rises globally, livestock farmers are keen on ensuring the health and productivity of their herds. Brucellosis can cause reproductive issues in cattle and sheep, leading to economic losses in the industry. The development and widespread adoption of effective Brucellosis vaccines offer a preventive solution, reducing the prevalence of the disease and promoting overall livestock well-being. This presents a lucrative market for vaccine manufacturers, as farmers increasingly prioritize disease management to enhance the sustainability and profitability of their livestock operations.

Threat:

Limited awareness and education

The limited awareness and education threat in the Brucellosis vaccine market arises from insufficient knowledge and understanding among stakeholders, including healthcare professionals and the public. This lack of awareness may hinder the adoption of brucellosis vaccines, leading to lower vaccination rates. Inadequate education about the severity of brucellosis and the benefits of vaccination can contribute to an underestimation of the disease's impact, potentially impeding efforts to control its spread. Addressing this threat requires targeted educational campaigns to enhance awareness among healthcare providers, policymakers, and the general population.

Covid-19 Impact:

The diversion of resources and focus towards combating the global health crisis has led to a slowdown in the development, production, and distribution of brucellosis vaccines. Research and investment priorities have shifted, affecting the overall progress and availability of vaccines for Brucellosis. Additionally, disruptions in supply chains and logistical challenges have further hindered vaccine accessibility. As efforts continue to address COVID-19, the Brucellosis vaccine market faces delays and uncertainties, potentially affecting the control of this bacterial infection in both human and animal populations.

The viral diseases segment is expected to be the largest during the forecast period

The viral diseases segment is experiencing notable growth due to increasing awareness and efforts to combat this bacterial infection. And encompassing innovative research and development targeting Brucella strains, has witnessed a surge in investment and advancements. Furthermore, this growth is driven by a collaborative approach between pharmaceutical companies, research institutions, and governmental initiatives to address the significant public health concern posed by brucellosis.

The animal care centers segment is expected to have the highest CAGR during the forecast period

The Animal Care Centers segment is experiencing notable growth due to increasing awareness and proactive measures taken to control the spread of brucellosis in animals. With a rising emphasis on animal health and welfare, veterinary clinics and care centers are actively incorporating brucellosis vaccination programs into their services. This surge is also driven by regulatory efforts to mitigate the economic and public health impacts of brucellosis. Additionally, as livestock and companion animal owners seek preventive solutions, the demand for brucellosis vaccines within animal care centers is expanding.

Region with largest share:

North America dominated the global market and is expected to retain its position during the forecast period. Potential factors contributing to growth includes increased awareness about brucellosis prevention, rising demand for livestock health management, and government initiatives promoting animal health. The region's advanced veterinary healthcare infrastructure and research capabilities also foster the development and adoption of brucellosis vaccines. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.

Region with highest CAGR:

The Asia Pacific is estimated to grow at a considerable growth rate in the market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Increasing demand for dairy and meat products, coupled with a surge in animal husbandry practices, has fueled the need for effective vaccines.

Key players in the market

Some of the key players in Brucellosis Vaccine market include Biogenesis-Bago, Biovet, Boehringer Ingelheim, Calier, Ceva Sante Animale, Colorado Serum, CZ Veterinaria, Hester Biosciences, Indian Immunologicals, Onderstepoort Biological, Qilu, SYVA Laboratorios, Technovax and Zoetis.

Key Developments:

In January 2024, Ceva Sante Animale, acquired US-based Scout Bio, a biotech company focused on pet therapies. The move represents a significant leap in innovation for Ceva, unlocking access to key advancements including a pipeline of monoclonal antibodies and gene therapy developments to address chronic diseases in pets.

In November 2023, Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM's foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.

Vaccine Types Covered:

  • DNA Vaccine
  • Subunit Vaccine
  • Inactivated
  • Live Attenuated
  • mRNA Vaccines
  • Vector Vaccine
  • Viral vector vaccines
  • Other Vaccine Types

Diseases Covered:

  • Viral Diseases
  • Bacterial Vaccines
  • Allergy Vaccines
  • Cancer Vaccines
  • Other Diseases

Distribution Channels Covered:

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Other Distribution Channels

Applications Covered:

  • Cattle
  • Goat
  • Horses
  • Sheep
  • Swine
  • Other Applications

End Users Covered:

  • Veterinary Hospitals & Clinics
  • Animal Care Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Brucellosis Vaccine Market, By Vaccine Type

  • 5.1 Introduction
  • 5.2 DNA Vaccine
  • 5.3 Subunit Vaccine
    • 5.3.1 Conjugate Vaccines
    • 5.3.2 Recombinant vaccines
    • 5.3.3 Toxoid vaccines
  • 5.4 Inactivated
  • 5.5 Live Attenuated
  • 5.6 mRNA Vaccines
  • 5.7 Vector Vaccine
  • 5.8 Viral vector vaccines
  • 5.9 Other Vaccine Types

6 Global Brucellosis Vaccine Market, By Disease

  • 6.1 Introduction
  • 6.2 Viral Diseases
    • 6.2.1 Covid-19
    • 6.2.2 Hepatitis
    • 6.2.3 Herpes Zoster
    • 6.2.4 Human Papilloma Virus
    • 6.2.5 Measles, Mumps, and Rubella
    • 6.2.6 Influenza
    • 6.2.7 Rotavirus
    • 6.2.8 Other Viral Diseases
  • 6.3 Bacterial Vaccines
    • 6.3.1 Diphtheria Pertussis Tetanus
    • 6.3.2 Pneumococcal Diseases
    • 6.3.3 Meningococcal Diseases
    • 6.3.4 Other Bacterial Vaccines
  • 6.4 Allergy Vaccines
  • 6.5 Cancer Vaccines
  • 6.6 Other Diseases

7 Global Brucellosis Vaccine Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital & Retail Pharmacies
  • 7.3 Government Suppliers
  • 7.4 Other Distribution Channels

8 Global Brucellosis Vaccine Market, By Application

  • 8.1 Introduction
  • 8.2 Cattle
  • 8.3 Goat
  • 8.4 Horses
  • 8.5 Sheep
  • 8.6 Swine
  • 8.7 Other Applications

9 Global Brucellosis Vaccine Market, By End User

  • 9.1 Introduction
  • 9.2 Veterinary Hospitals & Clinics
  • 9.3 Animal Care Centers
  • 9.4 Other End Users

10 Global Brucellosis Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Biogenesis-Bago
  • 12.2 Biovet
  • 12.3 Boehringer Ingelheim
  • 12.4 Calier
  • 12.5 Ceva Sante Animale
  • 12.6 Colorado Serum
  • 12.7 CZ Veterinaria
  • 12.8 Hester Biosciences
  • 12.9 Indian Immunologicals
  • 12.10 Onderstepoort Biological
  • 12.11 Qilu
  • 12.12 SYVA Laboratorios
  • 12.13 Technovax
  • 12.14 Zoetis

List of Tables

  • Table 1 Global Brucellosis Vaccine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Brucellosis Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
  • Table 3 Global Brucellosis Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
  • Table 4 Global Brucellosis Vaccine Market Outlook, By Subunit Vaccine (2021-2030) ($MN)
  • Table 5 Global Brucellosis Vaccine Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
  • Table 6 Global Brucellosis Vaccine Market Outlook, By Recombinant vaccines (2021-2030) ($MN)
  • Table 7 Global Brucellosis Vaccine Market Outlook, By Toxoid vaccines (2021-2030) ($MN)
  • Table 8 Global Brucellosis Vaccine Market Outlook, By Inactivated (2021-2030) ($MN)
  • Table 9 Global Brucellosis Vaccine Market Outlook, By Live Attenuated (2021-2030) ($MN)
  • Table 10 Global Brucellosis Vaccine Market Outlook, By mRNA Vaccines (2021-2030) ($MN)
  • Table 11 Global Brucellosis Vaccine Market Outlook, By Vector Vaccine (2021-2030) ($MN)
  • Table 12 Global Brucellosis Vaccine Market Outlook, By Viral vector vaccines (2021-2030) ($MN)
  • Table 13 Global Brucellosis Vaccine Market Outlook, By Other Vaccine Types (2021-2030) ($MN)
  • Table 14 Global Brucellosis Vaccine Market Outlook, By Disease (2021-2030) ($MN)
  • Table 15 Global Brucellosis Vaccine Market Outlook, By Viral Diseases (2021-2030) ($MN)
  • Table 16 Global Brucellosis Vaccine Market Outlook, By Covid-19 (2021-2030) ($MN)
  • Table 17 Global Brucellosis Vaccine Market Outlook, By Hepatitis (2021-2030) ($MN)
  • Table 18 Global Brucellosis Vaccine Market Outlook, By Herpes Zoster (2021-2030) ($MN)
  • Table 19 Global Brucellosis Vaccine Market Outlook, By Human Papilloma Virus (2021-2030) ($MN)
  • Table 20 Global Brucellosis Vaccine Market Outlook, By Measles, Mumps, and Rubella (2021-2030) ($MN)
  • Table 21 Global Brucellosis Vaccine Market Outlook, By Influenza (2021-2030) ($MN)
  • Table 22 Global Brucellosis Vaccine Market Outlook, By Rotavirus (2021-2030) ($MN)
  • Table 23 Global Brucellosis Vaccine Market Outlook, By Other Viral Diseases (2021-2030) ($MN)
  • Table 24 Global Brucellosis Vaccine Market Outlook, By Bacterial Vaccines (2021-2030) ($MN)
  • Table 25 Global Brucellosis Vaccine Market Outlook, By Diphtheria Pertussis Tetanus (2021-2030) ($MN)
  • Table 26 Global Brucellosis Vaccine Market Outlook, By Pneumococcal Diseases (2021-2030) ($MN)
  • Table 27 Global Brucellosis Vaccine Market Outlook, By Meningococcal Diseases (2021-2030) ($MN)
  • Table 28 Global Brucellosis Vaccine Market Outlook, By Other Bacterial Vaccines (2021-2030) ($MN)
  • Table 29 Global Brucellosis Vaccine Market Outlook, By Allergy Vaccines (2021-2030) ($MN)
  • Table 30 Global Brucellosis Vaccine Market Outlook, By Cancer Vaccines (2021-2030) ($MN)
  • Table 31 Global Brucellosis Vaccine Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 32 Global Brucellosis Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 33 Global Brucellosis Vaccine Market Outlook, By Hospital & Retail Pharmacies (2021-2030) ($MN)
  • Table 34 Global Brucellosis Vaccine Market Outlook, By Government Suppliers (2021-2030) ($MN)
  • Table 35 Global Brucellosis Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 36 Global Brucellosis Vaccine Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 Global Brucellosis Vaccine Market Outlook, By Cattle (2021-2030) ($MN)
  • Table 38 Global Brucellosis Vaccine Market Outlook, By Goat (2021-2030) ($MN)
  • Table 39 Global Brucellosis Vaccine Market Outlook, By Horses (2021-2030) ($MN)
  • Table 40 Global Brucellosis Vaccine Market Outlook, By Sheep (2021-2030) ($MN)
  • Table 41 Global Brucellosis Vaccine Market Outlook, By swine (2021-2030) ($MN)
  • Table 42 Global Brucellosis Vaccine Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 Global Brucellosis Vaccine Market Outlook, By End User (2021-2030) ($MN)
  • Table 44 Global Brucellosis Vaccine Market Outlook, By Veterinary Hospitals & Clinics (2021-2030) ($MN)
  • Table 45 Global Brucellosis Vaccine Market Outlook, By Animal Care Centers (2021-2030) ($MN)
  • Table 46 Global Brucellosis Vaccine Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.